Enhance your development by sharing ideas and best practice with your industry peers and vendors
Register yourself and a team online now!
Become a free member of Pharma IQ's online community.
Early Bird Discount
Register and pay by 27th June 2008 and receive up to £200 off!
Want to secure more funding for your antibodies research?
Then you need to attend Driving Commercial Value in Biotechs on July 7th 2008. Our cost effective, time efficient one-day event allows you to get expert advice from 14 different speakers and explore loads of different routes to funding, guided by those who have done it successfully!
Visit: www.iqpc.com/uk/biotech for more details.
Very worthwhile networking opportunity with peers with similar interests.
Claude Dufresne, Merck, Enhancing Drug Discovery Automation Conference, Nov 2007
‘According to a new report the therapeutic antibody market is expected to treble in size by 2010, as significant leaps forward coupled with safer and more effective humanised and fully human antibodies are pouring onto the market fulfilling their long-awaited commercial promise.’
Pharma IQ's Therapeutic Antibodies conference provides the best opportunity to link the strategies employed by both biotechnology and pharmaceutical firms to practical applications that you can use.
This informative and interactive two day conference provides attendees with an effective and relaxed forum in which they can hear from industry experts and exchange ideas with peers.
The expert speaker panel includes:
- William Strohl, Executive Director, Department of Biologics Research, Johnson & Johnson
- David Blakey, Senior Principal Scientist, AstraZeneca
- Dr Alastair Lawson, Director of Antibody Technology, UCB Celltech
- Dr Horst Lindhofer, Chief Executive Officer, TRION Pharma
- Dr Mike Clark, Reader in Therapeutic and Molecular Immunology, University of Cambridge
- Matthew Baker, Chief Scientific Officer, Antitope
- Professor Agamemnon Epenetos, Consultant Oncologist, Trojan Technologies
- Dr Nils Lonberg, SVP Scientific Director, Medarex
- Dr Victor S. Goldmacher, Senior Director, Cell Biology, ImmunoGen
- Dr Jerry W. Slootstra, Director Epitope Mapping and Protein Mimicry, Pepscan
- John Haurum, Chief Scientific Officer, Symphogen
- Philippe Stas, Chief Executive Officer, AlgoNomics
- Professor Dr Stefan Dübel, Institute ofBiochemistry and Biotechnology, Technical University of Braunschweig
- Dr Kerry Chester, Oncology Department, UCL Cancer Institute
- Dr Michel Cogné, Managing Director, Université de Limoges et Centre Hospitalier Universitaire Dupuytren
Benefits of attending
As one of the fastest growing segments of the pharma market, the value of therapeutic antibodies is expected to more than triple in value.
The success of current marketed products has led to escalation in antibody development, with more than 370 programs currently in the pipeline. Evolutions in innovation and business model dynamics will drive the sector's dominant position.
Pharma IQ’s Therapeutic Antibodies Conference is a must-attend event and will provide an excellent opportunity to network, enhance your company’s profile and keep you up-to-date on the latest issues in the market.
Who will be there?
VPs, Directors, Head and Managers of:
- Research and Development
- Pre-clinical development
- Clinical Development
- Antibody Development
- Product Development
- Manufacturing
- Drug Discovery
- Antibody Engineering
- Protein Engineering
- Immonology
- Clinical Diagnostics
Plus many more!
What will YOU take away from this event?
- The changing landscape, drivers and demand for therapeutic antibodies
- Reviewing the current state of regulations and intellectual property situation relating to Antibodies
- Assessing developments and advances in the discovery of Antibody Biopharmacueticals
- Engineering of Antibody Fc regions to optimise safety and efficacy
Don't miss this event because...
Therapeutic Antibodies 2008 will allow professionals working in this area to save valuable research time by taking in a large amount of information in a two day period. The interactive nature of the conference means that you can learn from your peers and share knowledge to facilitate effective development.
PLUS DO NOT MISS OUR CONFERENCE WORKSHOP: 30th September 2008 18:10 - 20:00
Preclinical Immunogenicity Testing Of Protein Therapuetics
Lead by Dr Frank Carr, Director, Biologics Research, Antitope Ltd
- Not sure about two days out of the office?
- Concerned about the relevance of the content?
- Struggling to justify the investment with your superiors?
IQPC has the benefit of 35 years of experience in hosting market leading conferences and will always endeavour to deliver material that is valuable and accessible in a practical format to provide insights and techniques that can be applied to your own organisation.
If you are not yet ready to register, feel free to request a reminder nearer the time .
Conference Partners
| sponsors |
Media Partners |
|
|
[ Register Now ]
· [ Next: Conference Day One: 30th September ]